mProX™ Human F2R Stable Cell Line

Product Information

Target Protein

F2R

Target Family

Protease-activated (Thrombin) Family

Target Protein Species

Human

Host Cell Type

MDA-MB-231; MCF-7; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Cardiovascular Research

Related Diseases

Thrombosis; Bernard-Soulier Syndrome

Gene ID

2149

UniProt ID

P25116

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PAR-1 was the first member of the protease-activated receptors family. Not only are all types of blood cells expressed with thrombin-activated PAR-1, but also the epithelium, neurons, astrocytes, and immune cells. In addition, the tumor microenvironment contains mast cells, macrophages, blood vessel myocytes, and ECs (Epithelial Cells) that are associated with cancer. PAR-1 raises thrombin and other growth factor levels in macrophages. Since then, much research has concentrated on the function of PAR-1 in tumor cells' biology as well as on PAR-1 agonists and inhibitors. Recent years have seen a surge in interest in drugs that target PAR-1, which is anticipated to lead to novel clinical treatment concepts. The customized F2R stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Jonathan

The F2R cell line surpassed my expectations in terms of sensitivity and ease of use. It's now an essential tool in our lab, and we plan to continue using it for future projects. Sep 07 2022

chat Verified Customer

chat Caroline

I have been using the F2R cell line for my research, and it has consistently provided reliable results. Apr 17 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 PAR1 Is an Invasogenic Factor in Breast Cancer Cells.

PAR1 siRNA was used to inhibit PAR1 expression in MDA-MB-231 cells as opposed to a control siRNA that inhibited firefly luciferase. Using flow cytometry, the surface expression of PAR1 and PAR4 following a 48-hour siRNA therapy was identified.

Ref: Boire, Adrienne, et al. "PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells." Cell 120.3 (2005): 303-313.

Pubmed: 15707890

DOI: 10.1016/j.cell.2004.12.018

Research Highlights

When RANKL is stimulated, F2r responds by blocking the F2r-Akt and F2r-NFκB signaling pathways, which results in a decrease in the production of osteoclast genes. A novel therapeutic strategy for bone illnesses including osteoporosis may involve targeting F2r.
Zhang, Yan, et al. "F2r negatively regulates osteoclastogenesis through inhibiting the Akt and NFκB signaling pathways." International journal of biological sciences 16.9 (2020): 1629.
Pubmed: 32226307 DOI: 10.7150/ijbs.41867

To look into the relationship between protease-activated receptor-1 (PAR-1) gene F2R polymorphisms and clopidogrel's effectiveness for TIA or mild stroke.
Pan, Yuesong, et al. "F2R polymorphisms and clopidogrel efficacy and safety in patients with minor stroke or TIA." Neurology 96.1 (2021): e1-e9.
Pubmed: 33093222 DOI: 10.1212/WNL.0000000000011078